SCHEMBL6604189

SCHEMBL6604189

CCOc1cc(-c2ccccc2)nn1CCOc1ccc(-c2ccc(OC)cc2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.43
NPBWR1 P48145 1/20 0.39
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
HPGD P15428 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
NPC1 O15118 1/20 0.38
STAT1 P42224 1/20 0.38
RAB9A P51151 1/20 0.38
MAPK1 P28482 1/20 0.38
LMNA P02545 1/20 0.38
CREBBP Q92793 1/20 0.38
ERN1 O75460 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LTB4R Q15722 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6602658 0.94 HPGD (0.42) MAPTALDH1A1PKMHPGDL3MBTL1
SCHEMBL6805998 0.90 HPGD (0.41) MAPTALDH1A1PKMHPGDL3MBTL1
SCHEMBL6804559 0.90 TP53 (0.43) MAPTERN1
SCHEMBL6604163 0.89 S1PR4 (0.40) MAPTALDH1A1HPGDL3MBTL1SMN1; SMN2
SCHEMBL6602333 0.87 HPGD (0.38) MAPTKDM4EHPGDL3MBTL1SMN1; SMN2
SCHEMBL6800862 0.87 NLRP3 (0.43) MAPTNPBWR1ALDH1A1KDM4EHPGD
SCHEMBL6805954 0.87 MRGPRX4 (0.38) MAPTHPGDL3MBTL1RAB9ACREBBP
SCHEMBL6607860 0.86 HPGD (0.40) MAPTALDH1A1PKMHPGDL3MBTL1
SCHEMBL6603655 0.86 HPGD (0.38) MAPTALDH1A1HPGDL3MBTL1SMN1; SMN2
SCHEMBL6601481 0.85 CYP11B1 (0.42) MAPTALDH1A1KDM4ETSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 MAPT 3013/4885NPBWR1 2015/4885ALDH1A1 758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.